Methods for therapeutic renal neuromodulation using neuromodulatory agents or drugs
Methods and apparatus are provided for treatment of heart arrhythmia via renal neuromodulation. Such neuromodulation may effectuate irreversible electroporation or electrofusion, ablation, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, such neuromodulation is achieved through application of an electric field. In some embodiments, such neuromodulation is achieved through application of neuromodulatory agents, of thermal energy and/or of high intensity focused ultrasound. In some embodiments, such neuromodulation is performed in a bilateral fashion.
1. A method for treating a human patient diagnosed with hypertension, the method comprising:
introducing a catheter having a plurality of infusion needles to a renal artery of the patient and proximate to target renal nerves;
delivering an ablative drug via the infusion needles to tissue external to the renal artery and in contact with the target renal nerves,
wherein the ablative drug at least partially ablates the target renal nerves; and
removing the catheter from the patient to conclude treatment after delivering the ablative drug.
2. The method of claim 1 wherein delivering the ablative drug and at least partially ablating the target renal nerves results in a therapeutically beneficial reduction in blood pressure of the patient.
3. The method of claim 1 wherein delivering an ablative drug via the infusion needles comprises delivering phenol.
4. The method of claim 1 wherein delivering an ablative drug via the infusion needles comprises delivering alcohol.
5. The method of claim 1 wherein delivering an ablative drug via the infusion needles comprises delivering a neurotoxin.
6. The method of claim 1 wherein delivering an ablative drug via the infusion needles comprises delivering a botulinum toxin.
7. The method of claim 1 wherein introducing a catheter having a plurality of infusion needles to a renal artery of the patient comprises delivering the catheter over a guidewire through an abdominal aorta of the patient and into the renal artery.
8. The method of claim 1 wherein delivering the ablative drug to the target renal nerves at least partially denervates a kidney of the patient.
9. The method of claim 1 wherein delivering the ablative drug and at least partially ablating the target renal nerves alters at least one of urine production, fluid retention, renin secretion, waste excretion, sodium retention, systemic vasoconstriction, renal function, heart function and blood pressure in the patient.
10. The method of claim 9 wherein altering urine production comprises increasing urine output.
11. The method of claim 9 wherein altering renin secretion comprises decreasing plasma renin level secretion.
12. The method of claim 9 wherein altering sodium retention comprises increasing sodium excretion.
13. The method of claim 1 wherein the renal artery is a first renal artery and the target renal nerves are first target renal nerves, and wherein the method further comprises:
introducing the catheter to a second renal artery of the patent and proximate to second target renal nerves after delivering the ablative drug via the infusion needles to tissue external to the first renal artery;
delivering the ablative drug via the infusion needles to tissue external to the second renal artery and in contact with the second target renal nerves,
wherein the ablative drug at least partially ablates the second target renal nerves; and
removing the catheter from the patient to conclude treatment after delivering the ablative drug to tissue external to the second renal artery.
14. A method for treating a human patient diagnosed with a cardio-renal disease or disorder, the method comprising:
delivering an agent to target renal nerves of the patient in an amount sufficient to at least partially ablate and thereby modulate neural function of the targeted renal nerves,
wherein modulating neural function of the targeted renal nerves results in a reduction in one or more symptoms associated with the patient's cardio-renal disease or disorder.
15. The method of claim 14 wherein delivering an agent to target renal nerves comprises localized delivery of the agent from a catheter within a renal artery of the patient.
16. The method of claim 14 wherein delivering an agent to target renal nerves of the patient comprises delivering a chemical that attenuates or blocks neural signals along the targeted renal nerves.
17. The method of claim 14 wherein the cardio-renal disease or disorder is hypertension.
18. The method of claim 14 wherein the cardio-renal disease or disorder is congestive heart failure.
19. The method of claim 14 wherein the cardio-renal disease or disorder is end-stage renal disease.